Related Experiment Videos
Abstract:
The multidrug-resistance (MDR) phenotype expressed in mammalian cell lines is complex. A cell selected with a single agent can acquire cross-resistance to a remarkably wide range of compounds which have no structural or functional similarities. The basis for cross-resistance seems to be a decreased net cellular accumulation of the drugs involved, and has been attributed to alterations in plasma membrane. An over-expressed plasma membrane P glycoprotein of relative molecular mass of 170 kD (Pgp) is consistently found in different MDR human and animal cell lines, and in transplantable tumors. Consequently, it has been postulated that Pgp directly or indirectly mediates MDR. This paper reviews the current knowledge on etiology, pathogenesis, diagnosis and therapy of MDR.
Insights
Multidrug resistance (MDR) in cells involves cross-resistance to diverse drugs, often due to altered plasma membranes. Overexpressed P-glycoprotein (Pgp) is linked to this complex MDR phenotype.
Area of Science:
- Cellular Biology
- Pharmacology
- Biochemistry
Context:
- Mammalian cell lines exhibit complex multidrug resistance (MDR).
- Acquired cross-resistance to structurally dissimilar drugs is a hallmark of MDR.
- This phenomenon is often linked to alterations in the cell's plasma membrane.
Purpose:
- To review the current understanding of multidrug resistance (MDR).
- To explore the etiology, pathogenesis, diagnosis, and therapy of MDR.
- To discuss the role of P-glycoprotein (Pgp) in mediating MDR.
Summary:
- Multidrug resistance (MDR) involves acquiring resistance to a wide array of drugs lacking structural similarities.
- A key feature of MDR is decreased net cellular drug accumulation, attributed to plasma membrane changes.
- Overexpression of P-glycoprotein (Pgp), a 170 kD plasma membrane protein, is consistently observed in MDR cells and tumors, suggesting its role in mediating MDR.
Impact:
- Provides a comprehensive overview of MDR, aiding researchers and clinicians.
- Highlights the central role of P-glycoprotein (Pgp) in MDR.
- Informs potential therapeutic strategies targeting MDR mechanisms.